Medtronic has announced the launch of its neurovascular Co-Lab platform, which is designed to accelerate “urgently needed” innovation in stroke care and treatment.
The company is harnessing its market-leading position and trusted partner reputation to create a platform that will ultimately advance technology concepts that have the highest potential to positively impact millions of stroke patients, as per a press release.
The Medtronic neurovascular Co-Lab platform is an always-on virtual portal for innovator submissions, which are then assessed and prioritised to determine a potential path forward. Chosen opportunities will be advanced based on their individual needs, including exposing innovators to Medtronic’s network of experts, thought leaders and partners for collaboration, clinical study funding, and strategic and directional guidance.
Innovators, entrepreneurs and physicians will be able to collaborate, enhance, and share their breakthrough concepts and products through the platform, the release notes.
Medtronic states that, with this launch, it is deepening its commitment to advance stroke innovation as the world prepares to recognise World Stroke Day on 29 October 2022.
“What is fascinating about the neurovascular field is that we still have so much to discover about the brain,” said Brett Wall, executive vice president and president of the Medtronic Neuroscience Portfolio. “Medtronic has always invested in innovative stroke treatment technologies leading the standard of care and advancing the practice of neurosurgery. The neurovascular market has enormous growth potential, and we invite innovative start-ups, physicians, venture-capital firms and inventors to collaborate with us as we set out to change stroke care as we know it today. With more than 90,000 employees across 150 countries—combined with our proven record in stroke innovation—Medtronic is positioned well to help address this urgent challenge.”
The platform will officially be launched tomorrow, on World Stroke Day 2022, according to Medtronic.
